A comparative in vitro drug release prospective with two different polymers for the development of floating single unit dosage form of imatinib mesylate for chronic myelogenous leukemia by Vinod, Kombath R et al.
Originales
A comparative in vitro drug release prospective with two different polymers for the 
development  of floating single unit dosage form of imatinib mesylate for chronic 
myelogenous leukemia 
Vinod KR, Santosh V, Sandhya S, Otilia BJ, David B, Padmasri A
Conocimiento sobre tabaco y sus métodos de deshabituación entre los estudiantes 
de 1º, 3º y 5º curso de Farmacia en España. Estudio PRECOTABAC. Parte II. 
Muñoz-Muñoz E, García-Jiménez E, Martínez-Martínez F, Espejo Guerrero J  
Formulation and evaluation of controlled release matrix tablet of Diltiazem HCl by 
using HPMC and Guar gum as polymeric matrix material.
Shah UH, Patel BK, Patel MR
Binding of desloratadine and atenolol with bovine serum albumin and their in-vitro 
interactions 
Shihab-us-Sakib K, Islam MA, Moniruzzaman M, Hussein A, Hossain M, Mazid MA
Analysis and evaluation of prescriptions in Al-Ahsa (Saudi Arabia)
Sangi S, Turki M, Otaibi G, Hazoom MAK, Harsha S
Artículo Especial
Vaginistis: Etiología, diagnóstico y profilasis




Ars Pharm. 2012; 53(4)






1A comparative in vitro drug release prospective with two different 
polymers for the development  of floating single unit dosage form 
of imatinib mesylate for chronic myelogenous leukemia
Kombath R Vinod1, Vasa Santosh1, Subhadra Sandhya2, Banji J Otilia3, Banji David3, Anugu Padmasri1
1. Department of Pharmaceutics, Nalanda College of Pharmacy, Nalgonda, AndhraPradesh, India; 2.Department of Pharmacognosy, 
Nalanda College of Pharmacy, Nalgonda, AndhraPradesh, India; 3.Department of Pharmacology, Nalanda College of Pharmacy, Nalgonda, 
AndhraPradesh, India.
Correspondence/Correspondencia: 
Kombath R Vinod 
HOD, Department of Pharmaceutics, 
Nalanda College of Pharmacy , Nalgonda, 
AndhraPradesh- 508001, India.
Telf: #91 9010055004







Objetivo. El propósito de este trabajo ha sido  elaborar un sistema de liberación gástrica de mesilato 
de imatinib. 
Material y Método. Se han elaborado comprimidos flotantes de mesilato de imatinib empleando 
HPMC K4M y HPMC K15M junto con excipientes efervescentes. Los excipientes celulósicos fueron 
seleccionados según su capacidad de formación de estructuras de gel y controladores de cesión. El 
bicarbonato de sodio se incorporó como agente efervescente. Se evaluaron la capacidad flotante de 
los comprimidos, uniformidad de peso, dureza, friabilidad, riqueza y velocidad de disolución. 
Resultados. Las formulaciones seleccionadas demostraron tener buenas propiedades físico-químicas 
incluyendo buena capacidad de flotación con un aumento de tamaño por captación de agua durante 
su disolución. Los comprimidos pueden flotar durante más de 12 horas. Los comprimidos con 
HPMC K4M tienen mayor capacidad de flotación que los obtenidos con HPMC K15M. Se puede 
controlar satisfactoriamente la cesión del fármaco. En un ensayo in vivo se ha demostrado que los 
comprimidos pueden estar 6 horas en el estómago.
Conclusión: La retención gástrica de la unidad de mesilato de imatinib se hace utilizando sistemas 
flotantes. HPMC K4 dio una mejor liberación,  hasta el 98,4% en 12 horas. Todos los comprimidos 
flotantes gastroretentivo mostraron  una buena flotación durante el período de liberación del 
fármaco.
PALABRAS CLAVE: Mesilato de imatinib, gastroretención, comprimidos flotantes, flotabilidad in vitro
ABSTRACT 
Aim: The purpose of this investigation was to prepare a gastroretentive drug delivery system of 
Imatinib mesylate.
Materials and Method: Floating tablets of imatinib mesylate were prepared employing HPMC K4M 
and HPMC K15M by effervescent technique; these grades of HPMC were evaluated for their gel 
forming properties. Sodium bicarbonate was incorporated as a gas-generating agent. The floating 
tablets were evaluated for uniformity of weight, hardness, friability, drug content, in vitro buoyancy 
and dissolution studies.
Results: The prepared tablets exhibited satisfactory physico-chemical characteristics. All the 
prepared batches showed good in vitro buoyancy. The tablet swelled radially and axially during in 
vitro buoyancy studies. It was observed that the tablet remained buoyant for >12 hours. The tablets 
with HPMC K4M were found to float for longer duration as compared with formulations containing 
HPMC K15M. The drug release from the tablets was sufficiently sustained and non-Fickian transport 
of the drug from tablets was confirmed. From the radiographic pictures obtained at different time 
intervals, it has been proved that that the tablet was floating during the observed time intervals up 
to 6h against all peristaltic movements. 
Conclusion: Gastric retention of Imatinib mesylate unit dosage form was achived by floatation. 
HPMC K4 gave better release up to 98.4% in 12 hrs. All the gastroretentive floating tablets showed 
good floatation during the period of drug release, and the drug release was found to follow non-
fickian diffusion type. 
KEY WORDS: Imatinib mesylate, gastroretention, floating tablets, in vitro buoyancy.
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INTRODUCTION
Imatinib mesylate is a protein-tyrosine kinase inhibitor; 
inhibits the abnormally functioning Bcr-Abl tyrosine 
kinase, which is produced by the Philadelphia chromosome 
abnormality found in chronic myeloid leukemia (CML). 
This drug inhibits cell proliferation and induces apoptosis 
(programmed cell death) in the Bcr-Abl cell lines and in the 
leukemic cells generated by CML, inhibits proliferation and 
induces apoptosis in gastrointestinal stromal tumor (GIST) 
cells, which express an activating c-kit mutation. More 
recently, the imatinib has been approved for the treatment 
of mesenchymal cell neoplasms of the intestinal tract. It has 
now been discovered that Imatinib mesylate can be used 
as a treatment for patients suffering from hepatic fibrosis 
based on its ability to down regulate stellate cell activation 
in culture and in vivo. The usual oral recommended dose 
of Imatinib for humans is between 50 and about 1600 mg/
day, in two or four doses. The formulations provide rapid 
dissolution of the active ingredient that in turn results in its 
rapid increase in blood plasma levels above the therapeutic 
steady state levels, immediately after administration 
followed by approaching a decrease in blood plasma levels 
up to subtherapeutic plasma levels after about twelve hours 
following oral administration, thus requiring additional 
dosing with the drug in accelerated or blast crisis phase 
of CML.
As Imatinib mesylate is very slightly soluble to insoluble 
in neutral/alkaline region of intestine where its absorption 
is maximum, it is not absorbed to the same extent once 
it passes the upper small intestine, especially with the 
conventional dosage forms. Imatinib must be continuously 
released in the stomach before it reaches the absorption 
window thus ensuring optimal bioavailability1, 2. Ironically, 
there is no reported work on Imatinib as gastroretentive 
dosage form. Hence, there is a call for developing a new 
formulation and its process for imatinib that maintains 
optimum therapeutic steady state plasma concentrations 
to avoid inter- patient variability and side effects by 
maintaining dosage form for 12 hours in the gastric region 
by designing controlled release gastroretentive drug 
delivery system, and therefore, research efforts have been 
focused on development of gastric retention platforms. 
In the present investigation, floating tablets of Imatinib 
mesylate were prepared by effervescent approach using 
HPMC K4M and HPMC K15M. The aim of the work 
was to evaluate the effect of gel-forming polymer HPMC 




Imatinib mesylate was received as a generous gift sample 
from Dysymmetrix Labs Pvt. Ltd, Hyderabad, India. HPMC 
K4M  and HPMC K15M were received as gift samples from 
Dysymmetrix Labs Pvt. Ltd, Hyderabad, India. Magnesium 
stearate, hydrochloric acid, Microcrystalline cellulose and 
sodium bicarbonate were purchased from SD Fine-Chem 
Ltd, Ahmedabad, India. Purified talc was purchased from 
E. Merck (India) Ltd., Mumbai. All other ingredients were 
of laboratory grade.
Formulation of imatinib myselate tablets
The Compositions of different formulation trials with 
different polymers were presented in the Table 1. Accurately 
weighed quantities of polymer, avicel were taken in a 
mortar and mixed geometrically. To this mixture required 
quantity of Imatinib mesylate was added and mixed 
slightly with pestle. This mixture was passed through 40# 
and later collected in a plastic bag and blended for 5 min. 
To this required amount of sodium bi carbonate and were 
added and again mixed for 5 min. Later required quantity 
of magnesium stearate, and talc were added and the final 
blend was again passed through 40#. Thus obtained 
blend was mixed thoroughly for 10 min and compressed 
into tablets with a same force using single punch tablet 
machine (Cadmach Machinery Ltd., Ahmedabad, India)3. 
The tablets were round and flat with an average diameter 
of 12.0 ± 0.1 mm and a thickness of 3.2 ± 0.2 mm.
FTIR study
Drug interaction studies were undertaken by Perkin-Elmer 
FTIR study to know the presence of any interaction of the 
drug with excipients used for preparing the tablets. For 
this the samples containing pure drug alone, formulation 
containing HPMC K4M, formulation containing HPMC 
K15M were analyzed in the spectral range 400 to 4000 Cm-1 
using KBr pellet technique 4.
Flow properties of powder blend
The flow properties of powder blend (before compression) 
were characterized in terms of angle of repose5, Carr index6 
and Hausner rati 7. 
Angle of repose Ɵ = tan-1 (h/r)
Where h is height of the pile and r is the radius of its base 
of pile.  Hausner ratio (HR) and Carr index (IC) were 
calculated according to the two equations given below:
HR= ρt/ ρb
IC = (ρt– ρb)/ ρt
Where ρt- tapped density and ρb- bulk density
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Ingredients
(mg per tablet)
F1 F2 F3 F4 F5 F6 F7 F8
Imatinib mesylate 100 100 100 100 100 100 100 100
HPMC K4M 50 60 70 80 - - - -
HPMC K15M - - - - 50 60 70 80
Sodium bicarbonate 20 20 20 20 20 20 20 20
Avicel 50 40 30 20 50 40 30 20
Characterization and evaluation of floating tablets
The prepared floating tablets were evaluated for uniformity 
of weight using 20 tablets, hardness (Monsanto tester) , 
friability using 10 tablets (Roche type friabilator), drug 
content, in vitro buoyancy6 and in vitro dissolution studies8-
10. The results were expressed as mean ± S.D. (n = 5). The 
in vitro buoyancy and floating lag time was determined 
by following procedure, the tablets were placed in a 100 
ml beaker containing pH 3 dissolution media. The time 
required for the tablet to rise to the surface and float was 
determined as floating lag time. The duration of time for 
which the dosage form constantly remained on the surface 
of medium was taken as the total floating time.
The drug content in each formulation was determined by 
triturating 20 tablets and powder equivalent to average 
weight was added in 100ml of 0.1N hydrochloric acid, 
followed by stirring for 30 minutes. The solution was 
filtered through a 0.45μ membrane filter, diluted suitably 
and the absorbance of resultant solution was measured 
spectrophotometrically at 236nm using 0.1 N hydrochloric 
acid as blank11-13.
The release rate of Imatinib mesylate from floating tablets 
were determined using USP Dissolution Testing Apparatus 
2 (paddle method; ELECTROLAB TDT-08L, Mumbai). 
The dissolution test was performed using 900 ml of pH 
3 dissolution media, at 37 ± 0.5°C and 50 rpm. Aliquots 
of 1 mL were withdrawn from the dissolution apparatus 
hourly and the samples were replaced with same volume 
of fresh dissolution medium. The samples were filtered 
through a 0.45μ membrane filter and diluted to a suitable 
concentration with 0.1N hydrochloric acid. Absorbance 
of these solutions was measured at 236 nm using a UV/
Vis spectrophotometer (ELICO SL 159, Mumbai Indian 
Equipment Corporation, Mumbai). Cumulative percentage 
drug release was calculated and the same was plotted 
against time14-16. Statistical analysis was carried out by 
using “GraphPad Instat” software. All the experimental 
data were expressed as mean ± SD.
Kinetic assessment 
To study the nature and release pattern of the drug, model 
fitting curves were used. 
Zero order model, Mt = Mc+ kot ,  Graph was plotted Mt Vs t
First order model, Mt = M0e-kt , Graph was plotted log Mt Vs t
Higuchi model, Mt = M0+ kHt 0.5 Graph was plotted Mt Vs t 0.5
Korsmeyer- Peppas model, Mt/ Ma =  kktn Graph was plotted 
log M t/ 100 Vs log T
Where Mt is the amount of drug released in time t, M0 is 
the initial amount of the drug, ko is the zero order release 
constant, k1 is the first order release constant, kH is the  
Higuchi rate constant, kk is the Korsmeyer- Peppas release 
constant and  n is the release exponent that characterizes 
the mechanism of drug release17, 18.
Radiographic studies
Institutional animal ethical committee certificate (NCOP/
IAEC/approved/11/2010) was obtained prior to the 
commencement of pharmacological studies. After 
overnight fasting, six healthy rabbits were taken and fed 
lightly. The tablets were given orally and allowed to take 
adequate amount of water 12-16. Water was given ad libitum. 
Radiographs were obtained at different time intervals like 
before the administration of tablet, 30min, 3rd h, 6 rd h and 
after 24 rd h. 
RESULTS 
The FTIR spectral graphs of pure drug (fig 1a) and 
formulations with two different grades of HPMC (K4M 
and K15M) are shown in figure 1A and 1B respectively. The 
powder blend prepared for compression of floating tablets 
was evaluated for their flow properties (Table 2). Angle 
of repose was in the range of 27.6° to 29.3° with powder 
blend containing HPMC K4M and 26.7° to 28.7° with 
HPMC K15M. Bulk density ranged between 0.56 to 0.58 
gm/cm3 with powder blend containing HPMC K4M and 
0.593 to 0.624 gm/cm3 with HPMC K15M. Tapped density 
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containing HPMC K4M and 0.667 to 0.692 gm/cm3 with 
HPMC K15M. Carr index and Hausner ratio were found to 
be in the range of 0.10 - 0.14 and1.12 -1.17 respectively for 
powder blend of different formulations. 
Evaluation of floating tablets
The results of the physical characterization of the tablets 
of both the formulation are summarized in Table 3. The 
weight of the tablet varied between 223 mg to 232 mg for 
different formulations with low standard deviation values. 
The hardness for different formulations was found to be 
between 6.10 to 6.15 kg/ cm2. The friability was below 0.5% 
for all the formulations. The drug content varied between 
97.23 to 99.54 mg in different formulations. All the tablets 
were prepared by effervescent approach. 
All the batches of tablets were found to exhibit short 
floating lag times in the range 64 to 122 s, for F1 and F3 
respectively. The tablets with low-viscosity grade HPMC 
K4M exhibited short floating lag time and floated for 
longer duration as compared with formulations containing 
high viscosity grade HPMC K15M. This indicated that 
the molecular weight distribution or viscosity of the gel-
forming polymer HPMC influenced the in vitro buoyancy. 
The drug release from floating tablets was found to be 
85.3 to 99.6% for F1 to F4 with HPMC K4M. The drug 
release from formulations containing high-viscosity grade 
Figure 1.  Fourier Transfer 
Infrared spectra of pure drug (A), 
drug + HPMC K4M (B) , drug + 
HPMC K15M (C)
FTIR done as a part of 
preformulation studies indicates 
there is no pharmaceutical 
interaction.
HPMC K15M ( F5 to F8 ) varied between 78.2 to 99.3%. 
The prepared formulations sustained the drug release for a 
period of > 12 hours. Comparing the two different grades 
of HPMC ( K4M and K15M ), it was found that F2 & F6 
showed better release characteristics with excellent in vitro 
buoyancy. 
DISCUSSION 
The work was intended to prepare gastroretentive floating 
tablets using HPMC K4M and HPMC K15M in various 
proportions. FTIR spectrogram of pure drug Imatinib 
and two formulations of both grades of  HPMC were 
comparable with respect to the peek intensity, revealed 
there is no interaction of the drug with the excipients used 
in the formulations. The flotation buoyancy of the tablets 
was achieved by effervescent technique using sodium 
bicarbonate. The magnesium stearate and talc were used 
as lubricant and glidant, respectively. Flow properties of 
granules are inevitable parameters in the preparation of 
tablet formulation. The values of flow properties of all 
parameters indicated that the prepared powder blend 
exhibited good flow properties, since the values were 
within the acceptable standard range.
The variation in weight was within the range of ± 5% 
complying with pharmacopoeia specifications, indicating 
uniformity in weight. Hardness and friability tests revealed 
satisfactory mechanical strength and good mechanical 
Ars Pharm. 2012; 53(4): 01-07.
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5Table 3. Physical evaluation parameters of imatinib mesylate tablets 
Table 2. Flow properties of powder blend in the formulation of tablet









F1 28.7° 0.561 ± 0.032 0.652 ± 0.083 1.16 0.13
F2 29.3° 0.567 ± 0.045 0.634 ± 0.043 1.11 0.11
F3 27.6° 0.574 ± 0.058 0.674 ± 0.048 1.17 0.14
F4 28.1° 0.582 ± 0.026 0.652 ± 0.083 1.12 0.10
F5 28.4° 0.593 ± 0.053 0.667 ± 0.063 1.12 0.11
F6 27.9° 0.607 ± 0.057 0.679 ± 0.057 1.11 0.10
F7 26.7° 0.601 ± 0.048 0.682 ± 0.049 1.13 0.12
F8 28.7° 0.593 ± 0.043 0.692 ± 0.075 1.16 0.14
Results are represented as mean ± SD; n=3













Drug release kinetic 
modeling
F1 224.60 ± 2.12 6.10 ± 0.24 3.38 ± 0.05 0.1 97.23 Peppas (0.9959)
F2 228.33 ± 1.45 6.15 ± 0.18 3.37 ± 0.06 0.27 99.12 Peppas (0.9891)
F3 225.80 ± 1.63 6.25 ± 0.37 3.28 ± 0.03 0.19 98.32 Zero order (0.9815)
F4 223.09 ± 2.43 6.45 ± 0.26 3.38 ± 0.04 0.22 99.54 Peppas (0.9919)
F5 226.05 ± 2.51 6.25 ± 0.54 3.33 ± 0.06 0.18 99.43 Peppas (0.9936)
F6 224.37 ± 3.89 6.18 ± 0.35 3.45 ± 0.06 0.21 98.67 Peppas (0.9966)
F7 229.09 ± 3.12 6.50 ± 0.48 3.38 ± 0.05 0.16 98.97 Peppas (0.9882)          
F8 232.65 ± 2.20 6.45 ± 0.25 3.35 ± 0.25 0.16 98.28 Peppas(0.9925)
resistance of the tablet respectively. Drug content with low 
coefficient of variation indicated content uniformity in the 
prepared batches. 
Sodium bicarbonate was added as a gas-generating agent. 
Sodium bicarbonate induced carbon dioxide generation 
in presence of dissolution medium ( pH 3 ). The sodium 
bicarbonate provided desired floating ability and therefore 
this combination was selected for the formulation of the 
floating tablets.
The tablet swelled radically and axially during in vitro 
buoyancy studies. Fig 2: shows the floating nature of the 
tablets. The liberated gas must have trapped and protected 
within the gel, formed by hydration of polymer ( HPMC ), 
thus decreasing the density of the tablet below 1 and tablet 
became buoyant. From in vitro drug release profile of all 
the formulations could be better expressed by Korsemeyer- 
Peppas model as they showed a good linearity with ‘R’ 
value of 0.988-0.9961. F3 formulation alone was observed 
to follow zero order kinetics.
Figure 2. In vitro buoyancy test of Imatinib mesylate 
floating tablets in 0.1 N Hcl after 10 sec ( A ) 64 sec ( B ) 
2 min ( C ) 4 hours (D) 8 hours ( E) and 12 hours ( F ). 
Floatation studies clearly demonstrates the dosage started 
submerging and floating in 64 sec and 2 min respectively and 
kept buoyant up to 12 hrs.
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the comparatively narrow alimentary track, tablets were 
incorporated with barium sulphate as a radio-opaque 
agent and the size of the tablets were reduced. Adequate 
precautions were taken for the specially designed tablets 
to get comparative in-vitro buoyancy behavior with that 
of the original tablets in discussion. By reducing size of 
the tablet, authors claim that the gastroretentive behavior 
was achieved not by inability of the swollen tablet to leave 
the stomach, but rather with its floating properties. X ray 
was also taken prior to the per oral administration of the 
tablet to make sure that the observed opaque substance in 
the stomach of rabbit is due to the administered product 
but not some foreign matter already existed. From the 
radiographic pictures obtained at different time intervals, it 
has been proved that that the tablet was floating during the 
observed time intervals up to 6h. The position of the tablet 
was found to have distorted towards right but found to 
retain at the 8th thoraxic vertebrae. It can be hypothetically 
assumed that gel forming property of HPMC might have 
contributed for this floatation behaviour. The radiographic 
pictures are shown in Fig.3. It was also observed that tablet 
was cleared after 24 hours (Fig 3e). The tablet has overcome 
the peristaltic movements of the GIT and enabled to float 
for considerable time before emptying the gastric region. 
But while no in vitro – in vivo correlation was found at any 
period.
CONCLUSION
Gastric retention of Imatinib mesylate unit dosage form 
was achived by floatation.  HPMC K4 gave better release 
up to 98.4% in 12 hrs. It has to be concluded that objective 
of the present research in delevoping gastroretentive drug 
delivery system was achieved by formulating floating 
tablets of Imatinib mesylate. All the gastroretentive floating 
Figure 3. Radiographic pictures of floating tablets pre administration of tablet (a), post administration sessions at 
30min (b), 3 h (c), 6h (d) and 24h (e) ( The position of tablet has been indicated as a cicle). 
It is evident that the size of the tablet increased perhaps due to swelling but found to float around at 8th thoracic vertebral 
position. 
tablets showed good floatation during the period of drug 
release, and the drug release was found to follow non-
fickian diffusion type. To achieve good gastroretention, 
floating dosage forms has to be taken along with plenty of 
water, and low viscous diet.
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